Lesson plan

Fluoxakalner

Fluoxakalner is a K v 7.2 and K v 7.3 potassium channel opener which is under investigation for potential medical use. Its for opening K v 7.2 and K v 7.3 channels has been found to be 360 nM. The drug produces analgesic effects in rodents and without causing sedation or locomotor changes. In addition, it did not inhibit various cardiac ion channels. The chemical synthesis of fluoxakalner has been described. Fluoxakalner was first described in the scientific literature by Wei Xiang and colleagues in 2026. It was developed as a replacement for retigabine, which was withdrawn from the market due to toxicity. Fluoxakalner avoids oxidative metabolites like retigabine's thought to be responsible for said toxicity.

Back to article

Article summary

Fluoxakalner is a K v 7.2 and K v 7.3 potassium channel opener which is under investigation for potential medical use. Its for opening K v 7.2 and K v 7.3 channels has been found to be 360 nM. The drug produces analgesic effects in rodents and without causing sedation or locomotor changes. In addition, it did not inhibit various cardiac ion channels. The chemical synthesis of fluoxakalner has been described. Fluoxakalner was first described in the scientific literature by Wei Xiang and colleagues in 2026. It was developed as a replacement for retigabine, which was withdrawn from the market due to toxicity. Fluoxakalner avoids oxidative metabolites like retigabine's thought to be responsible for said toxicity.

Key claims

No claims recorded.

Discussion questions

  1. Summarise the article in your own words. Which single claim would you verify first, and why?
  2. Which claim in this article is most likely to be revised as the sources update? How would you check its current status?
  3. If two sources disagreed about one of these facts, what would you need in order to trust one over the other?

Bibliography

No sources recorded.

Key claims and bibliography are generated from the same tracked claims and sources as the article page.